<DOC>
	<DOCNO>NCT01309022</DOCNO>
	<brief_summary>The purpose protocol provide continue acess immunosuppressive medication subject completed/closed trial ITN005CT ( NIS01 , NCT00014911 ) . THIS PROTOCOL DOES NOT PROVIDE MEDICINES TO DIABETES PATIENTS WHO DID NOT PARTICIPATE IN ITN005CT .</brief_summary>
	<brief_title>Immunosuppressive Medications Participants ITN005CT ( NCT00014911 )</brief_title>
	<detailed_description>Study acronym : EXIIST - Extended Immunosuppression Islet Transplantation Islet transplantation experimental therapy people difficult control Type 1 diabetes ( T1D ) . Insulin produce cell ( islet ) isolate pancreas . After cell prepared , islet put subject 's liver . These transplanted islet may produce insulin subject 's islet longer make . In order help keep function transplant islet , immunosuppressive medication must give indefinitely long study doctor determines necessary . The medication serve modify immune system normally try destroy ( reject ) new islet . Participants study receive three islet cell infusion previous participant ITN005CT ( NIS01 ) protocol . They also receive maintenance immunosuppressive treatment regimen consist combination orally administer drug ( tacrolimus ( Prograf速 ) , sirolimus ( Rapamune速 ) , mycophenolate mofetil ( MMF , Cellcept速 ) , and/or mycophenolic acid ( MPA , Myfortic速 ) . ) This protocol provide way supply immunosuppressive medication subject whose islet continue function make C-peptide . Routine study follow-up visit occur annual -as warrant basis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Participation clinical trial ITN005CT ( reference : ClinicalTrials.gov record NCT00014911 ) Harvard University ( Massachusetts General Hospital ) , Washington University , University Miami . Immunosuppressive regimen consist single agent combination among follow : tacrolimus , sirolimus , mycophenolate mofetil , mycophenolic acid . Willingness participant use approve method contraception , , 12 week study participation . Peak Cpeptide &gt; 0.1 pmol/mL mixed meal tolerance test ( MMTT ) within 12 month screen visit . Inability understand sign inform consent document study . Any medical condition opinion investigator preclude participation . Serum creatinine &gt; 1.6 mg/dL Insulin requirement &gt; 1.0 IU/kg/day Hemoglobin A1C ( HbA1C ) result &gt; 12 % Hypoglycemia unawareness define absence adequate autonomic symptom plasma glucose level &lt; 54 mg/dL require treatment glucagon , outside assistance , treatment emergency room hospital within 12month period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 1</keyword>
	<keyword>T1D</keyword>
	<keyword>T1DM</keyword>
	<keyword>Islets Langerhans Transplantation</keyword>
	<keyword>Pancreatic Islets Transplantation</keyword>
	<keyword>Islet Transplant</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>Mycophenolic acid</keyword>
</DOC>